摘要
目的观察银杏叶提取物对大鼠肝缺血再灌注NF-κB p65表达的影响并探讨其作用机制。方法将45只SD雄性大鼠分为对照组,模型组,银杏叶提取物低剂量给药组、中剂量给药组、高剂量给药组。参考Pringle's法建立模型。测定血清丙氨酸氨基转移酶(ALT)、天冬氨酸氨基转移酶(AST)和肝组织丙二醛(MDA)、超氧化物歧化酶(SOD);肝组织进行光镜检查;Western blot检测肝组织中核内NF-κB p65表达水平。结果肝缺血再灌注后,ALT和AST水平及MDA含量显著增高,SOD活性则下降;光镜下,可见到肝窦和中央静脉严重淤血,肝细胞水肿,变性及坏死;肝组织核内NF-κB p65表达水平升高。中剂量和高剂量给药组与模型组比较,ALT和AST水平及MDA含量升高受到显著抑制,SOD活性增加,肝组织病理变化显示肝损伤减轻,且核内NF-κB p65表达水平下降,呈剂量依赖性,以上变化有显著性差异。结论银杏叶提取物可减轻大鼠肝缺血再灌损伤程度,可能机制是通过增强自由基清除作用,减少NF-κB p65表达水平。
Objective To investigate the protective effect of Ginkgo biloba extract（ EGb） on the expression of NF-κB p65 against hepatic ischemia / reperfusion injury in rats. Try to evaluate the mechanism of the hepatic ischemia / reperfusion injury in rats. Methods Models of rats with hepatic ischemia reperfusion injury were established with the Pringle＇s method. 45 healthy male SD rats were randomly divided into 5 groups：（ 1） sham group;（ 2） HIRI group;（ 3） low dosing group;（ 4） normal dosing group;（ 5） high dosing group. Serum alanine aminotransferase（ ALT） 、aspartate transaminase（ AST） and maleic dialdehyde（ MDA） 、superoxide dismutase（ SOD） in liver tissue were respectively measured in each group. The activity of NF-κB p65 was determined by western blot,also histological examination of the liver was made. Results In the HIRI group,the levels of ALT、AST、MDA and the activity of NF-κB p65 increased remarkably,however,the levels of SOD decreased obviously; hepatocytes were arranged in turbulence,hepatic lobules were distorted,hepatocytes and endothelial cells underwent swelling or necrosis. The nomal and high dosing group significantly prevented increase of ALT 、AST 、MDA、NF-κB p65 and reduction of SOD activity. Pathological changes of hepatocytes and endothelial cells in liver induced by ischemia reperfusion were also preveted in the these groups. Conclusion The EGb can protect rats from hepatic ischemia / reperfusion injury,the mechanism may be related to anti-oxygen-derived free radicals and inhibiting the expressions of NF-κB p65.
出处
《时珍国医国药》
CAS
CSCD
北大核心
2015年第12期2865-2867,共3页
Lishizhen Medicine and Materia Medica Research
基金
湖北省卫生厅重点资助项目(No.2012Z-Y43)
